Clinical Trials · NCT04615871
Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Vladimír Džavík
- Enrollment
- 400
- Start date
- Sep 2021
- Locations
- 10 sites, 4 countries
- Primary endpoint
- Composite of death or mechanical ventilation